6 documents

Read All
08:00 , Feb 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology ...
Read More
08:00 , Dec 17, 2007 |  BC Week In Review  |  Clinical News

ASF-1057: Phase III started

Astion began an international Phase III trial in 500 patients with moderate to severe facial seborrheic dermatitis to compare ASF-1057 vs. neutral moisturizing cream or placebo. Astion Pharma A/S, Copenhagen, Denmark   Product: ASF-1057   Business:...
Read More
08:00 , Dec 17, 2007 |  BC Week In Review  |  Clinical News

ASF-1057: Phase III started

Astion began an international Phase III trial in 700 patients with moderate to severe facial seborrheic dermatitis to compare topical ASF-1057 vs. 2% ketoconazole cream or placebo. Astion Pharma A/S, Copenhagen, Denmark   Product: ASF-1057...
Read More
08:00 , Oct 30, 2006 |  BC Week In Review  |  Clinical News

ASF-1057: Phase IIb started

Astion began a double-blind, placebo-controlled, French Phase IIb trial (Study 204) in 104 patients. Subjects will receive 1 of 3 doses of ASF-1057 or placebo once-daily for 3 weeks. Astion Pharma A/S, Copenhagen, Denmark   Product:...
Read More
08:00 , Oct 30, 2006 |  BC Week In Review  |  Clinical News

ASF-1057: Phase IIb start

Early next year, Astion will begin a double-blind, placebo-controlled, U.K. Phase IIb trial (Study 206) in 100 patients. Astion Pharma A/S, Copenhagen, Denmark   Product: ASF-1057   Business: Dermatology   Molecular target: NA   Description: Non-steroidal anti-inflammatory compound...
Read More
08:00 , Oct 30, 2006 |  BC Week In Review  |  Clinical News

ASF-1057: Phase IIb start

By year end, Astion will begin a double-blind, placebo-controlled, French Phase IIb trial (Study 205) in 60 patients. Subjects will receive 1 of 2 doses of ASF-1057 or placebo twice-daily for 3 weeks. Astion Pharma...
Read More